Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* BMI ≥25 and ≤ 40 kg/m2~* concomitant medical conditions associated with NAFLD~Exclusion Criteria:~* Evidence of other causes of liver disease such as Alcoholic steatohepatitis, (de)compensated cirrhosis, active viral hepatitis~* Any condition possibly affecting drug absorption~* Unstable liver function tests~* Recent cardiovascular event(s),~* Malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive medication for 6 weeks
- DGAT2i (25 mg BID) + ACCi (10 mg BID) (Type: EXPERIMENTAL): Participants will receive medication for 6 weeks
- DGAT2i (100 mg BID) + ACCi (10 mg BID) (Type: EXPERIMENTAL): Participants will receive medication for 6 weeks
- DGAT2i (300 mg QD) + ACCi (20 mg QD) (Type: EXPERIMENTAL): Participants will receive medication for 6 weeks
- DGAT2i (300 mg BID) + ACCi (10 mg BID) (Type: EXPERIMENTAL): Participants will receive medication for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).